» Articles » PMID: 36943668

Mitochondrial Dysfunction and Parkinson's Disease: Pathogenesis and Therapeutic Strategies

Overview
Journal Neurochem Res
Specialties Chemistry
Neurology
Date 2023 Mar 21
PMID 36943668
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is a common age-related neurodegenerative disorder whose pathogenesis is not completely understood. Mitochondrial dysfunction and increased oxidative stress have been considered as major causes and central events responsible for the progressive degeneration of dopaminergic (DA) neurons in PD. Therefore, investigating mitochondrial disorders plays a role in understanding the pathogenesis of PD and can be an important therapeutic target for this disease. This study discusses the effect of environmental, genetic and biological factors on mitochondrial dysfunction and also focuses on the mitochondrial molecular mechanisms underlying neurodegeneration, and its possible therapeutic targets in PD, including reactive oxygen species generation, calcium overload, inflammasome activation, apoptosis, mitophagy, mitochondrial biogenesis, and mitochondrial dynamics. Other potential therapeutic strategies such as mitochondrial transfer/transplantation, targeting microRNAs, using stem cells, photobiomodulation, diet, and exercise were also discussed in this review, which may provide valuable insights into clinical aspects. A better understanding of the roles of mitochondria in the pathophysiology of PD may provide a rationale for designing novel therapeutic interventions in our fight against PD.

Citing Articles

Energy metabolism in health and diseases.

Liu H, Wang S, Wang J, Guo X, Song Y, Fu K Signal Transduct Target Ther. 2025; 10(1):69.

PMID: 39966374 PMC: 11836267. DOI: 10.1038/s41392-025-02141-x.


GPX3 as a Novel and Potential Therapeutic Target in the Shared Molecular Mechanisms of Traumatic Brain Injury and Parkinson's Disease.

Wang Y, Fang J, Yuan Q, Yu J, Hu J J Inflamm Res. 2025; 18:1911-1928.

PMID: 39935526 PMC: 11812561. DOI: 10.2147/JIR.S506891.


Association between deep gray matter iron deposition and clinical symptoms in Parkinson's disease: a quantitative susceptibility mapping study.

Zhao H, Ji Q, Jia Z, Shen L Front Neurol. 2025; 15():1442903.

PMID: 39835146 PMC: 11743366. DOI: 10.3389/fneur.2024.1442903.


Biological Function Analysis of MicroRNAs and Proteins in the Cerebrospinal Fluid of Patients with Parkinson's Disease.

Hwang J, Kim S, George N, Kwon M, Jang Y, Lee S Int J Mol Sci. 2025; 25(24.

PMID: 39769025 PMC: 11678473. DOI: 10.3390/ijms252413260.


TFE3-mediated neuroprotection: Clearance of aggregated α-synuclein and accumulated mitochondria in the AAV-α-synuclein model of Parkinson's disease.

He X, Chen M, Fan Y, Wu B, Dong Z Genes Dis. 2025; 12(2):101429.

PMID: 39759118 PMC: 11697191. DOI: 10.1016/j.gendis.2024.101429.


References
1.
Ball N, Teo W, Chandra S, Chapman J . Parkinson's Disease and the Environment. Front Neurol. 2019; 10:218. PMC: 6433887. DOI: 10.3389/fneur.2019.00218. View

2.
Lotankar S, Prabhavalkar K, Bhatt L . Biomarkers for Parkinson's Disease: Recent Advancement. Neurosci Bull. 2017; 33(5):585-597. PMC: 5636742. DOI: 10.1007/s12264-017-0183-5. View

3.
Choudhury G, Daadi M . Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease. PLoS One. 2018; 13(8):e0202770. PMC: 6107255. DOI: 10.1371/journal.pone.0202770. View

4.
Pacelli C, Giguere N, Bourque M, Levesque M, Slack R, Trudeau L . Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons. Curr Biol. 2015; 25(18):2349-60. DOI: 10.1016/j.cub.2015.07.050. View

5.
Paoletti F, Gaetani L, Parnetti L . The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers. Biomolecules. 2020; 10(2). PMC: 7072459. DOI: 10.3390/biom10020335. View